Skip to main content
Zhejiang CONBA Pharmaceutical Co.,Ltd. logo

Zhejiang CONBA Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 600572 ISIN · CNE000001H86 LEI · 300300LYPEXDXC8YSI39 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,787 across all filing types
Latest filing 2026-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600572

About Zhejiang CONBA Pharmaceutical Co.,Ltd.

https://www.conbapharm.com/

Zhejiang CONBA Pharmaceutical Co.,Ltd. specializes in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products, with a primary focus on modern Chinese medicine and chemical drugs. The company's portfolio encompasses therapeutic areas such as cardiovascular health, digestive systems, respiratory care, and urology. Notable products include its proprietary pollen preparations for prostate health and high-purity Ginkgo biloba extracts. CONBA integrates traditional botanical knowledge with advanced extraction and formulation technologies to produce standardized health solutions. Its operations span the entire value chain, including medicinal plant cultivation, active pharmaceutical ingredient production, and finished dosage manufacturing. The company serves both clinical and over-the-counter markets, emphasizing quality control and innovation in botanical medicine.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (audit firm) for the upcoming fiscal year 2026. It details the audit firm's background, personnel, business scale, integrity records, independence, audit fees, and the approval process by the board and audit committee. It does not contain any actual financial statements or audit results but is a formal announcement about the selection and continuation of the audit firm for the company's financial report and internal control audit. The document length is 2809 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits best under the category of Audit Report / Information (AR) as it relates to audit information and appointment of auditors, but it is not a full annual report or audit report itself. However, since it is specifically about the audit firm appointment and audit-related information, AR is the most appropriate classification rather than a regulatory filing or report publication announcement. FY 2026
2026-04-22 Chinese
关于子公司替米沙坦氨氯地平片（Ⅱ）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Kang En Bei Pharmaceutical Co., Ltd. regarding its subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's registration, approval, and expected impact on the company. The document is relatively short (1392 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory approval. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-09 Chinese
关于2026年第一季度股票期权激励计划自主行权结果暨股份变动公告
Director's Dealing Classification · 95% confidence The document is an announcement from Zhejiang Kang En Bei Pharmaceutical Co., Ltd. regarding the results of stock option exercises in the first quarter of 2026. It details the number of shares exercised, the stock option plan's history, approvals, and related disclosures. It includes specifics about share registration, stock option prices, and the impact on share capital and fundraising. The document is a formal disclosure of share transactions related to stock option exercises by company insiders and employees, including changes in shareholding and capital structure due to these exercises. It is not a full financial report, earnings release, or management discussion, but a detailed announcement of share transactions by directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length and detail support a high confidence classification.
2026-04-01 Chinese
关于2022年股票期权激励计划限制行权期间的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Zhejiang Kang En Bei Pharmaceutical Co., Ltd. regarding restrictions on the exercise period of its 2022 stock option incentive plan. It references regulatory rules from the China Securities Regulatory Commission and the Shanghai branch of the China Securities Depository and Clearing Corporation. The content focuses on the limitation of stock option exercises during a specific period and does not contain financial statements or detailed financial data. The document length is short (707 characters) and it serves as a notification about stock option exercise restrictions rather than a full report or detailed financial disclosure. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is about stock option exercise restrictions rather than new share issuance or capital changes.
2026-03-31 Chinese
关于股东减持股份结果的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholder's share reduction plan. It details the number of shares held before and after the reduction, the percentage of total shares, the dates of the reduction, and confirms compliance with relevant laws and regulations. It does not contain financial statements or performance data but focuses on shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2026-03-10 Chinese
关于持股5%以上股东权益变动触及1%刻度的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a disclosure announcement regarding changes in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding percentages, compliance with regulations, and confirms no impact on control or governance. The document is titled as a "提示性公告" (prompting announcement) about shareholding changes touching a 1% threshold. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but a regulatory announcement about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 2610 characters, which is relatively short and consistent with a notification rather than a full report.
2026-03-06 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.